PsyBio Therapeutics Increases Intellectual Property Portfolio with Filing of Novel Genetic Optimization Pathways for Psychedelic Medication Biosynthesis
Patent portfolio now includes four pending provisionals and one pending non-provisional patent application
PsyBio Therapeutics Corp.(CVE: PSYB)(OTCMKTS: PSYBF), an intellectual property based biotechnology company pioneering the next generation of targeted psychoactive medications, announced today that it has filed a new provisional patent application with the U.S. Patent and Trademark Office entitled Optimized Methods for the Production of Psilocybin and its Intermediates or Side Products. This filing increases the Company’s licensed patent portfolio to four pending provisional patents and one pending non-provisional patent with the U.S. Patent and Trademark Office as the Company continues to build its platform around bacterial-based synthesis of therapeutic tryptamines.
Psychedelics have shown promise for the potential treatment of a myriad of health challenges including mental health disorders such as post-traumatic stress disorder, anxiety, treatment resistant depression, and addiction. These small biomolecules are difficult to mass produce through chemical means or through extraction from the native organism. By utilizing genetically modified bacteria, PsyBio has developed a patent pending methodology to produce high concentrations of targeted potential therapeutics through fermentation with the goal of developing them for potential human therapy. The Company is tech transferring the first two of its lead compounds, psilocybin and norbaeocystin, into process development and scaled manufacturing.
By building upon PsyBio’s platform technology, we are in a unique position to leverage the value of naturally occurring tryptamines by utilizing their innate synergy to build potentially improved therapeutics targeted across a wide range of health challenges. Based on the established literature, successful preclinical results, and recent technology transfer to globally acclaimed development facilities, we are preparing the first of several packages for submission to the U.S. Food and Drug Administration (the “FDA”) in the coming quarter in anticipation of upcoming clinical trials.
Dr. Michael Spigarelli, Chief Medical Officer of PsyBio
“PsyBio has assembled, by hiring and collaboration, a premier team of engineers, scientists and regulatory experts dedicated to discovery, optimization, and development of new therapeutics based on tryptamine inspired molecules for a myriad of health challenges,” stated Evan Levine, Chief Executive Officer of PsyBio. “We continue to utilize sound scientific methodologies to discover new potential medications by resourcing our areas of expertise in metabolic engineering, chemistry, biology, and neuropsychology. The team has published and filed intellectual property on the most efficient methods to produce tryptamine compounds based on published data and continually builds on progress through targeted research and development efforts with the Jones and McMurray Labs at Miami University.”
To view the original press release in its entirety click here
